NewAmsterdam Pharma (NAMS) Assets Average (2022 - 2026)
NewAmsterdam Pharma (NAMS) posted Assets Average of $751.0 million for Q1 2026, down 3.46% sequentially from $777.9 million in Q4 2025, and down 10.76% YoY from $841.5 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Assets Average (2022 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Assets Average for 4 years, with the latest figure at $751.0 million in Q1 2026.
- Quarterly Assets Average fell 10.76% year-over-year to $751.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $751.0 million (down 10.76% YoY) and the FY2025 annual result came in at $817.0 million, up 34.84% from the prior year.
- Assets Average retreated to $751.0 million in Q1 2026 per NAMS's latest filing, from $777.9 million in the prior quarter.
- Over five years, Assets Average peaked at $841.5 million in Q1 2025 and troughed at $305.4 million in Q4 2022.
- A 4-year average of $627.3 million and a median of $701.4 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2025 and 2026: Assets Average soared 101.43% in 2025, then declined 10.76% in 2026.
- Over 4 years, Assets Average stood at $305.4 million in 2022, then jumped by 113.48% to $651.9 million in 2024, then gained by 19.32% to $777.9 million in 2025, then declined by 3.46% to $751.0 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $751.0 million, $777.9 million, and $800.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | 718.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 718.55 Mn |
| Mar 31, 2026 | 750.96 Mn |
| Dec 31, 2025 | 777.86 Mn |
| Sep 30, 2025 | 800.77 Mn |
| Jun 30, 2025 | 816.76 Mn |
| Mar 31, 2025 | 841.52 Mn |
| Dec 31, 2024 | 651.91 Mn |
| Sep 30, 2024 | 442.94 Mn |
| Jun 30, 2024 | 467.58 Mn |
| Mar 31, 2024 | 417.78 Mn |
| Dec 31, 2022 | 305.37 Mn |